Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19188233 | 0.82 | ZDHHC7 (0.34) | ZDHHC7CA1CA2SMN1; SMN2 | |
| SCHEMBL18930120 | 0.80 | SMN1; SMN2 (0.34) | ZDHHC7CA1CA2SMN1; SMN2KMT2A | |
| SCHEMBL11320047 | 0.76 | SMN1; SMN2 (0.39) | ZDHHC7CA1CA2SMN1; SMN2RECQL | |
| SCHEMBL5531442 | 0.76 | ZDHHC7 (0.43) | ZDHHC7CA1CA2SMN1; SMN2KMT2A | |
| SCHEMBL18930119 | 0.74 | CA14 (0.32) | CA1CA2CA12CA14 | |
| SCHEMBL30170510 | 0.73 | SMN1; SMN2 (0.42) | ZDHHC7CA1CA2SMN1; SMN2KMT2A | |
| SCHEMBL11287379 | 0.73 | SMN1; SMN2 (0.40) | ZDHHC7CA1CA2SMN1; SMN2KMT2A | |
| SCHEMBL28301320 | 0.73 | SMN1; SMN2 (0.42) | ZDHHC7CA1CA2SMN1; SMN2KMT2A | |
| SCHEMBL21598012 | 0.70 | SMN1; SMN2 (0.37) | ZDHHC7CA1CA2SMN1; SMN2RECQL | |
| SCHEMBL8948329 | 0.69 | SMN1; SMN2 (0.40) | ZDHHC7CA1CA2SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157264-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9498541-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150352223-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2015-12-10 | — | — | US | disclosed |
| US-8236319-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | ZDHHC7 2098/4885CA1 284/4885CA2 779/4885 |
| US-20150352223-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | ZDHHC7 2098/4885CA1 284/4885CA2 779/4885 |
| US-20170157264-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | ZDHHC7 2098/4885CA1 284/4885CA2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.